Genprex shares up 11.36% intraday after diabetes gene therapy project reaches clinical milestone and GPX-002 shows positive preclinical data in animal studies.

Genprex surged 11.36% intraday, driven by two key updates: 1) On January 7, 2026, the company announced a clinical development milestone for its diabetes gene therapy program, advancing future scale-up studies; 2) On January 6, 2026, it reported positive preliminary preclinical data for GPX-002 in type 2 diabetes animal models, demonstrating proof-of-concept in non-human primates. Genprex is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes.